Morse Asset Management Inc Buys Shares of 158,819 Emergent BioSolutions Inc. (NYSE:EBS)

Morse Asset Management Inc acquired a new stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 158,819 shares of the biopharmaceutical company's stock, valued at approximately $1,518,000. Morse Asset Management Inc owned about 0.29% of Emergent BioSolutions at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in EBS. Barclays PLC grew its stake in Emergent BioSolutions by 361.6% in the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company's stock valued at $329,000 after acquiring an additional 30,792 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Emergent BioSolutions by 3.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company's stock worth $7,328,000 after purchasing an additional 24,985 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Emergent BioSolutions during the 4th quarter worth about $1,831,000. New York State Common Retirement Fund boosted its stake in shares of Emergent BioSolutions by 41.7% during the 4th quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company's stock worth $2,928,000 after purchasing an additional 90,113 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. acquired a new stake in shares of Emergent BioSolutions during the 4th quarter worth about $201,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. StockNews.com cut shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, April 1st.

Insider Activity at Emergent BioSolutions

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the sale, the director now directly owns 101,100 shares in the company, valued at approximately $589,413. The trade was a 25.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.20% of the company's stock.

Emergent BioSolutions Stock Up 21.2%

NYSE:EBS traded up $1.17 during trading hours on Friday, hitting $6.66. The stock had a trading volume of 2,949,897 shares, compared to its average volume of 1,872,074. Emergent BioSolutions Inc. has a 1-year low of $4.02 and a 1-year high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company has a market cap of $361.22 million, a PE ratio of -1.62 and a beta of 2.09. The business has a 50 day simple moving average of $5.16 and a two-hundred day simple moving average of $7.79.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, topping analysts' consensus estimates of $0.49 by $0.22. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The business had revenue of $222.20 million during the quarter, compared to the consensus estimate of $218.50 million. Analysts predict that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Emergent BioSolutions declared that its Board of Directors has authorized a share buyback program on Monday, March 31st that authorizes the company to repurchase $50.00 million in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy up to 19% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's management believes its stock is undervalued.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.